We’ve reviewed the available evidence on GLP-1 receptor agonists and muscle outcomes in people with MASLD, and what we’ve found so far is that the research is too inconsistent and poorly designed to draw clear conclusions [1]. While 34 studies or assertions point to this limitation, none have contradicted it, meaning the pattern we see is one of uncertainty, not disagreement. The studies that exist vary widely in how they measure muscle mass, strength, or function — some use scans, others rely on self-reports or indirect markers. Many don’t control for factors like diet, physical activity, or baseline health, which can strongly influence muscle outcomes. Some studies are short-term, while others lack enough participants to detect meaningful changes. Without standardized methods or longer follow-up, it’s not possible to tell whether any observed changes in muscle are directly tied to the medication, weight loss, or something else entirely. We also don’t see consistent reporting of muscle-specific results across studies. When muscle data is included, it’s often secondary — not the main focus — making it harder to interpret. There’s no clear signal that GLP-1 receptor agonists help, harm, or leave muscle unchanged in MASLD because the foundation of the evidence isn’t strong enough to support a pattern. What this means for someone considering these medications is that while they may help with liver fat or blood sugar, we can’t say yet how they affect muscle based on current data. More carefully designed studies — with consistent measurements, longer duration, and muscle outcomes as a primary goal — are needed before we can understand this relationship better.